Comment: MCS110 is a myeloid cell targeting agent, specifically an IgG1 kappa monoclonal antibody against the ligand CSF-1 (a.k.a.
M-CSF). It is being investigated for its immuno-oncology potential. This is one of the antibody constructs claimed in patent WO2007016240 [
1].